Home > Boards > Canadian > Biotechs >

Procyon Biopharma Inc. (TSX:PBP)

TSX:PBP RSS Feed
Add TSX:PBP Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/26/2020 3:42:52 AM - Followers: 1 - Board type: Free - Posts Today: 0

http://www.procyonbiopharma.com/ http://www.procyonbiopharma.com/procyon_sitemap.htm Procyon BioPharma Inc. is a Montreal based cancer therapeutics company focused on advancing several platform technologies that have potential to treat, diagnose and prevent cancer. Advancing innovative and powerful anti-cancer technologies ™ ---------- Procyon has established leadership in the development of two substantial anti-cancer technology platforms with therapeutic and diagnostic applications that are based on naturally occurring cancer-fighting molecules found within the human body. These anti-cancer platforms involve Prostate Secretory Protein (PSP94) and Anti-nuclear Auto-antibodies (ANAs). PSP94 is a naturally occurring human protein that binds to the surface of cancerous prostate cells and inhibits their growth. In pre-clinical animal studies, researchers have demonstrated that PSP94 reduced the growth of implanted prostate tumours (derived from human prostate cancer cell lines) by as much as 50%. The Company plans to initiate clinical trials in humans with PSP94 later this year, focusing on the incurable hormone-resistant prostate tumour market as the first approved indication. The ANA technology platform is based on the discovery of naturally occurring antibodies that bind to nucleosomes, small particles of nuclear material on the surface of cancer cells. Cancer cells may attach nucleosomes to their cell surface to assist them in evading detection by the immune system, because nucleosomes have the ability to suppress the immune system's response to abnormal cells. By selectively binding to cancer cells, ANAs may strongly enhance the immune system's response to cancer. In preclinical research to date, Procyon BioPharma scientists have demonstrated that ANAs specifically bind to a broad range of cancer cells and initiate an immune response to the malignant cells without any perceived damage to normal cells. The ANA technology has the potential to treat several major cancers, including lymphoma, leukemia, colon, prostate and breast, which affect approximately 1.6 million people each year worldwide. The ANA technology is based on a series of discoveries by Dr. Vladimir Torchilin and colleagues at Harvard Medical School and the Massachusetts General Hospital in Boston. Oncologic has patented this technology in the US. PBI has subsequently acquired Oncologic. The Company plans to file an Investigational New Drug Application (IND) and initiate human clinic
TSX:PBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSX:PBP News: Equity CEFs: The Insanity Of CEF Investors - Part II 04/13/2015 11:44:00 AM
TSX:PBP News: ProMetic to Commercially Launch Fibrinogen in the Fourth Quarter of 2014 07/10/2014 08:08:01 AM
TSX:PBP News: Invesco PowerShares Lists First-of-Its-Kind ETF Referencing the Morgan Stanley Multi-Strategy Alternative Index 05/29/2014 09:30:00 AM
TSX:PBP News: Invesco PowerShares to Launch Multi-Strategy Alternative ETF 05/14/2014 09:00:00 AM
TSX:PBP News: Invesco PowerShares Expands Access-Suite Listing First Variable-Rate Preferred ETF 05/01/2014 09:30:00 AM
PostSubject
#8   Agreed, I'm on the fence right now but Jwit56 02/26/20 03:42:52 AM
#6   i like how PBP broke out. Looks like flyon 07/06/03 10:26:18 PM
#5   Croesus I: geoffb 01/21/03 04:12:11 PM
#4   &.... any comments on ONC.to Croesus I 04/02/02 09:10:47 PM
#3   I came across this ad in the London thebeach2 08/25/01 05:45:05 PM
#2   This was posted from a guy at Procyon's thebeach2 08/20/01 05:11:04 PM
#1   Procyon Biopharma (PBP - TSE) thebeach2 07/30/01 06:53:28 PM
PostSubject
Consent Preferences